𝔖 Bobbio Scriptorium
✦   LIBER   ✦

RNA-mediated neurodegeneration in fragile X-associated tremor/ataxia syndrome

✍ Scribed by Yujing Li; Peng Jin

Book ID
113506057
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
404 KB
Volume
1462
Category
Article
ISSN
0006-8993

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fragile X–Associated Tremor/Ataxia Syndr
Fragile X–Associated Tremor/Ataxia Syndrome
✍ Wang, Jun Yi; Hessl, David; Schneider, Andrea; Tassone, Flora; Hagerman, Randi J 📂 Article 📅 2013 🏛 American Medical Association 🌐 English ⚖ 266 KB
Fragile X-associated Tremor/Ataxia Syndr
Fragile X-associated Tremor/Ataxia Syndrome (FXTAS)
✍ Hagerman, Paul J. ;Hagerman, Randi J. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract Carriers of fragile X mental retardation 1 (__FMR1__) premutation alleles (55 to 200 CGG repeats) are generally spared the more serious neurodevelopmental problems associated with the full‐mutation carriers (>200 repeats) of fragile X syndrome. However, some adult male premutation carri

Intrafamilial variability in fragile X–a
Intrafamilial variability in fragile X–associated tremor/ataxia syndrome
✍ Nils Peters; Christoph Kamm; Friedrich Asmus; Elke Holinski-Feder; Eduard Kraft; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

## Abstract Fragile X–associated tremor/ataxia syndrome (FXTAS) is a progressive adult‐onset tremor/ataxia syndrome caused by premutations in the __FMR1__ gene. In cranial MRI, the most characteristic findings are bilateral T2 hyperintense lesions within the middle cerebellar peduncles. Here we pre

Symptomatic treatment in the fragile X–a
Symptomatic treatment in the fragile X–associated tremor/ataxia syndrome
✍ Deborah A. Hall; Elizabeth Berry-Kravis; Randi J. Hagerman; Paul J. Hagerman; Ca 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

## Abstract There is no established treatment for the neurological features of the recently discovered fragile X–associated tremor/ataxia syndrome (FXTAS). Fifty‐six patients with FXTAS completed a questionnaire to determine whether any medications had been effective for neurological symptoms. Of 1